1. Serum P-glycoprotein level: a potential biomarker of DMARD failure in patients with rheumatoid arthritis
- Author
-
Jorge I. Gamez-Nava, Esther N Sanchez-Rodriguez, José Francisco Muñoz-Valle, Sergio Ramón Gutiérrez-Ureña, José Clemente Vásquez-Jiménez, Sergio Cerpa-Cruz, N. A. Rodriguez-Jimenez, Erika Anita Aguilar-Chavez, M. L. Vazquez-Villegas, Laura Gonzalez-Lopez, Edsaul Emilio Perez-Guerrero, Ana Miriam Saldaña-Cruz, N. S. Fajardo-Robledo, Ernesto Germán Cardona-Muñoz, and M. Ramirez-Villafaña
- Subjects
musculoskeletal diseases ,0301 basic medicine ,Allergy ,medicine.medical_specialty ,Immunology ,Drug resistance ,Logistic regression ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Pharmacology (medical) ,skin and connective tissue diseases ,Prospective cohort study ,P-glycoprotein ,030203 arthritis & rheumatology ,Pharmacology ,biology ,business.industry ,Confounding ,medicine.disease ,Rheumatology ,030104 developmental biology ,Rheumatoid arthritis ,biology.protein ,business - Abstract
To evaluate the utility of elevated serum P-glycoprotein (P-gp) as a risk marker of therapeutic response failure in rheumatoid arthritis (RA) patients treated with disease-modifying antirheumatic drugs (DMARDs). A cross-sectional study was conducted in 151 RA patients. Patients were classified into two groups according to the response achieved in terms of the disease activity score (DAS)28 after ≥ 6 months: (1) patients with a therapeutic response to DMARDs, with DAS28
- Published
- 2018
- Full Text
- View/download PDF